CRMD Stock Risk & Deep Value Analysis
CorMedix Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About CRMD Stock
We analyzed CorMedix Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran CRMD through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is CRMD Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
Competitive Risk
Low
Execution Risk
High
Regulatory Risk
Low
What Are the Red Flags for CRMD?
- ⚠
Slower-than-expected commercial uptake or market penetration for DefenCath.
- ⚠
Unexpected manufacturing or supply chain issues impacting product availability.
- ⚠
Higher-than-anticipated cash burn requiring significant dilutive financing rounds.
Unlock CRMD Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does CorMedix Inc (CRMD) Do?
Market Cap
$762.68M
Sector
Healthcare
Industry
Biotechnology
Employees
64
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Visit CorMedix Inc WebsiteIs CRMD Stock Undervalued?
Unlock the full AI analysis for CRMD
Get the complete DVR score, risk analysis, and more
Is CRMD Financially Healthy?
P/E Ratio
4.38
Does CRMD Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is primarily driven by intellectual property (patents and QIDP exclusivity), first-mover advantage, and the inherent switching costs for healthcare providers adopting a new standard of care. This should provide a durable advantage for at least 10-15 years.
Moat Erosion Risks
- •Expiration of QIDP exclusivity and key patents allowing for generic or biosimilar competition.
- •Development of alternative preventative treatments or superior catheter technologies.
- •Lack of widespread adoption despite clinical benefits, due to cost or implementation hurdles.
CRMD Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive CRMD Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (estimated early May 2026) - focus on initial DefenCath sales figures.
- •Expansion of U.S. sales force and physician education initiatives.
- •Announcements of key hospital system formulary adoptions.
Medium-Term (6-18 months)
- •Q2 and Q3 2026 Earnings Reports demonstrating accelerating DefenCath sales growth.
- •Potential strategic partnerships for international distribution or expanded indications.
- •Positive real-world evidence and physician testimonials emerging from early adoption.
Long-Term (18+ months)
- •Establishment of DefenCath as the standard of care for CRBSI prevention in hemodialysis.
- •Further pipeline development or acquisition to leverage commercial infrastructure.
- •Achieving sustained profitability and positive free cash flow.
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for CRMD?
- ✓
Acceleration in DefenCath quarterly sales revenue and sequential growth rates.
- ✓
Positive commentary on formulary wins and increasing physician adoption.
- ✓
Effective cash management and demonstration of a clear path to profitability.
Bull Case Analysis
See what could go right with Premium
Compare CRMD to Similar Stocks
See how CorMedix Inc stacks up against related companies in our head-to-head analysis.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for CRMD (CorMedix Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
